Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2939 views | HTML 4233 views | ?
Nina A. Sibbesen1, Katharina L. Kopp1, Ivan V. Litvinov2, Lars Jønson3, Andreas Willerslev-Olsen1, Simon Fredholm1, David L. Petersen1, Claudia Nastasi1, Thorbjørn Krejsgaard1, Lise M. Lindahl4, Robert Gniadecki5, Nigel P. Mongan6, Denis Sasseville2, Mariusz A. Wasik7, Lars Iversen4, Charlotte M. Bonefeld1, Carsten Geisler1, Anders Woetmann1 and Niels Odum1
1 Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
2 Division of Dermatology, McGill University Health Centre, Montréal, Quebec, Canada
3 Departmen of Molecular Medicine, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark
4 Department of Dermatology, Aarhus University Hospital, Skejby, Aarhus, Denmark
5 Departmen of Dermatology, Copenhagen University Hospital, Bispebjerg, Copenhagen, Denmark
6 Faculty of Medicine and Health Science, School of Veterinary Medicine and Science, University of Nottingham, Loughborough, United Kingdom
7 Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
Niels Odum, email:
Keywords: miR-22, cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF), STAT3, STAT5, JAK3
Received: March 09, 2015 Accepted: April 22, 2015 Published: May 12, 2015
Aberrant activation of Janus kinase-3 (Jak3) and its key down-stream effectors, Signal Transducer and Activator of Transcription-3 (STAT3) and STAT5, is a key feature of malignant transformation in cutaneous T-cell lymphoma (CTCL). However, it remains only partially understood how Jak3/STAT activation promotes lymphomagenesis. Recently, non-coding microRNAs (miRNAs) have been implicated in the pathogenesis of this malignancy. Here, we show that (i) malignant T cells display a decreased expression of a tumor suppressor miRNA, miR-22, when compared to non-malignant T cells, (ii) STAT5 binds the promoter of the miR-22 host gene, and (iii) inhibition of Jak3, STAT3, and STAT5 triggers increased expression of pri-miR-22 and miR-22. Curcumin, a nutrient with anti-Jak3 activity and histone deacetylase inhibitors (HDACi) also trigger increased expression of pri-miR-22 and miR-22. Transfection of malignant T cells with recombinant miR-22 inhibits the expression of validated miR-22 targets including NCoA1, a transcriptional co-activator in others cancers, as well as HDAC6, MAX, MYCBP, PTEN, and CDK2, which have all been implicated in CTCL pathogenesis. In conclusion, we provide the first evidence that de-regulated Jak3/STAT3/STAT5 signalling in CTCL cells represses the expression of the gene encoding miR-22, a novel tumor suppressor miRNA.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.